Apr 13, 2021

Featuring perspectives from Drs Harold J Burstein and Lisa Carey on the following topics:

• ER-Positive, HER2-Negative Breast Cancer
• • Introduction (0:00)
  • CDK4/6 inhibitors for ER-positive breast cancer (3:53)
  • Role of PI3K inhibitors for ER-positive metastatic breast cancer (mBC) (13:31)
  • Use of genomic assays for patients with ER-positive breast cancer (17:48)
• HER2-Positive Breast Cancer
• • Treatment of early-stage disease; role of neoadjuvant therapy (23:35)
  • Management of HER2-positive mBC (27:23)
• Triple-Negative Breast Cancer
• • Immunotherapy for advanced triple-negative breast cancer (TNBC) (39:30)
  • Neoadjuvant immunotherapy for TNBC (42:59)
  • PARP inhibition for TNBC (48:37)
  • Efficacy of sacituzumab govitecan in TNBC (54:15)

CME information and select publications